Eosinophil count combined with routine indicators enhances early risk prediction value for ARDS in ICU patients: a retrospective cohort study
Abstract
Abstract Objectives This study aims to systematically evaluate the incremental value of admission eosinopenia EOS(−) in enhancing the predictive efficacy of early-stage acute respiratory distress syndrome (ARDS) risk models for ICU patients. Methods This study employed a single-center retrospective cohort design, enrolling 482 adult ICU patients between 2020 and 2023. Using Cox proportional hazards regression, we constructed and compared three models: Model 1 (baseline clinical model) included age, pneumonia, sepsis, and SOFA score; Model 2 added lymphocytes and eosinophils to Model 1; Model 3 further adjusted for BMI and diabetes. Predictive performance was assessed using the C-index, net reclassification improvement (NRI), and integrated discrimination improvement (IDI), and validated internally. Results C-statistics for Models 1, 2, and 3 were 0.683, 0.710, and 0.729, respectively. Model 3 demonstrated optimal performance (NRI=0.185, p=0.004), with an adjusted C-statistic of 0.695. Multivariate analysis identified age, pneumonia, and sepsis as independent ARDS risk factors, while EOS(−) showed non-independence. Results from competing risks analysis were consistent with the primary analysis conclusions. Conclusions Although eosinopenia is not an independent predictor of ARDS, it provides incremental information for early risk stratification based on conventional clinical factors, thereby aiding in the identification of high-risk patients.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 482 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.